Skip to content 
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California. more
| Time Frame | AMGN | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 0.39% | 0.71% | 1.64% |
| 1-Month Return | -4.18% | -4% | -2.94% |
| 3-Month Return | -12.73% | 0.84% | 3.53% |
| 6-Month Return | 1.68% | 12.62% | 22.95% |
| 1-Year Return | 16.86% | 7.99% | 26.43% |
| 3-Year Return | 16.31% | 18.97% | 26.19% |
| 5-Year Return | 73.38% | 71.39% | 86.42% |
| 10-Year Return | 219.53% | 184.83% | 224.48% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 23.36B | 25.42B | 25.98B | 26.32B | 28.19B | [{"date":"2019-12-31","value":82.87,"profit":true},{"date":"2020-12-31","value":90.19,"profit":true},{"date":"2021-12-31","value":92.16,"profit":true},{"date":"2022-12-31","value":93.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Cost of Revenue | 4.36B | 6.16B | 6.45B | 6.41B | 8.45B | [{"date":"2019-12-31","value":51.54,"profit":true},{"date":"2020-12-31","value":72.88,"profit":true},{"date":"2021-12-31","value":76.37,"profit":true},{"date":"2022-12-31","value":75.8,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Gross Profit | 19.01B | 19.27B | 19.52B | 19.92B | 19.74B | [{"date":"2019-12-31","value":95.43,"profit":true},{"date":"2020-12-31","value":96.73,"profit":true},{"date":"2021-12-31","value":98.03,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":99.11,"profit":true}] |
| Gross Margin | 81.35% | 75.77% | 75.16% | 75.66% | 70.02% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":93.14,"profit":true},{"date":"2021-12-31","value":92.38,"profit":true},{"date":"2022-12-31","value":93.01,"profit":true},{"date":"2023-12-31","value":86.07,"profit":true}] |
| Operating Expenses | 9.33B | 10.13B | 10.38B | 10.35B | 11.84B | [{"date":"2019-12-31","value":78.8,"profit":true},{"date":"2020-12-31","value":85.51,"profit":true},{"date":"2021-12-31","value":87.66,"profit":true},{"date":"2022-12-31","value":87.41,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Income | 9.67B | 5.79B | 6.00B | 5.33B | 7.90B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":59.89,"profit":true},{"date":"2021-12-31","value":62.07,"profit":true},{"date":"2022-12-31","value":55.15,"profit":true},{"date":"2023-12-31","value":81.63,"profit":true}] |
| Total Non-Operating Income/Expense | (1.07B) | 1.33B | (501.00M) | 605.00M | (2.51B) | [{"date":"2019-12-31","value":-80.42,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-37.58,"profit":false},{"date":"2022-12-31","value":45.39,"profit":true},{"date":"2023-12-31","value":-188.37,"profit":false}] |
| Pre-Tax Income | 9.14B | 8.13B | 6.70B | 7.35B | 7.86B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":89,"profit":true},{"date":"2021-12-31","value":73.33,"profit":true},{"date":"2022-12-31","value":80.39,"profit":true},{"date":"2023-12-31","value":85.96,"profit":true}] |
| Income Taxes | 1.30B | 869.00M | 808.00M | 794.00M | 1.14B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":67.05,"profit":true},{"date":"2021-12-31","value":62.35,"profit":true},{"date":"2022-12-31","value":61.27,"profit":true},{"date":"2023-12-31","value":87.81,"profit":true}] |
| Income After Taxes | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.63,"profit":true},{"date":"2021-12-31","value":75.15,"profit":true},{"date":"2022-12-31","value":83.55,"profit":true},{"date":"2023-12-31","value":85.65,"profit":true}] |
| Income From Continuous Operations | 7.84B | 7.26B | 5.89B | 6.55B | 7.57B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.63,"profit":true},{"date":"2021-12-31","value":75.15,"profit":true},{"date":"2022-12-31","value":83.55,"profit":true},{"date":"2023-12-31","value":96.48,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | 7.84B | 7.26B | 5.89B | 6.55B | 6.72B | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.63,"profit":true},{"date":"2021-12-31","value":75.15,"profit":true},{"date":"2022-12-31","value":83.55,"profit":true},{"date":"2023-12-31","value":85.65,"profit":true}] |
| EPS (Diluted) | 14.83 | 16.60 | 17.11 | 17.69 | 18.65 | [{"date":"2019-12-31","value":79.52,"profit":true},{"date":"2020-12-31","value":89.01,"profit":true},{"date":"2021-12-31","value":91.74,"profit":true},{"date":"2022-12-31","value":94.85,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| AMGN | |
|---|---|
| Cash Ratio | 0.60 |
| Current Ratio | 1.65 |
| Quick Ratio | 1.13 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| AMGN | |
|---|---|
| ROA (LTM) | 6.29% |
| ROE (LTM) | 135.79% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| AMGN | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.94 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.06 |
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 15.59 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| AMGN | |
|---|---|
| Trailing PE | 21.88 |
| Forward PE | 13.77 |
| P/S (TTM) | 5.08 |
| P/B | 22.99 |
| Price/FCF | 507 |
| EV/R | 6.99 |
| EV/Ebitda | 13.31 |
| PEG | 6.96 |
The last time I spoke about the top blue-chip stocks to buy on dips, I highlighted opportunity in the 2024 Dogs of the Dow . As I noted at the time , “Made up of the hardest-hit Dow stocks, which also pay out hefty dividend yields, you buy the Dogs at the start of the year, and cash out at the end of the year with hopeful wins in hand. In 2023, the Dogs of the Dow returned about 10.1%, as compared to the 14.4% gains on the overall Dow Jones Industrial Average . ” As for 2024 year to date, the top Dogs and the broader index have been a bit volatile. All thanks to incessant volatility, geopolitical tensions, and uncertainty over interest rate cuts. In fact, since the year began, the Dow Jones is up about 2%. Meanwhile, the Dogs are up an average of 5.3%, even more once you factor in dividends. While a good number of the Dogs have been performing well, others have some catching up to do after pulling back with the broader market. Here are three of the blue-chip stocks to buy on dips today.
Drugmakers like Novo Nordisk and Amgen are capitalizing on the success of groundbreaking obesity drugs with plans to release an additional 13 treatments in the coming years.
There is always a constant search for dependable prospects that offer stability and advancement. In the middle of this hunt, dividend stocks with growth stand out as possible bright spots that give investors a means to achieve solid returns and reliable income streams. Three exceptional businesses light up the scene in this domain with their steadfast dedication to growth and shareholder rewards. The first one, a key player in the communication services industry, demonstrates a strategic shift towards content and experiences in addition to steady dividend growth. Second, with its aggressive shop growth plan locally and globally, the next one is the perfect example of market expansion. Additionally, its global retail sales have grown considerably, demonstrating its ability to take market share. Lastly, the third company, a behemoth in the healthcare industry, exhibits a strategic vision through its regional growth and acquisitions. Meanwhile, its notable volume growth in strategic areas highlights its effective market penetration tactics.
Dividend investing can be a profitable strategy for traders, providing an extra source of income alongside potential stock gains. Amgen … Continue reading The post This biotech high-dividend stock is beating S&P 500 appeared first on Finbold .
In the biotech and pharmaceutical world, FDA approval is the number one needle mover for drug stocks. Why? Because FDA approval for a drug or treatment can bring years or even decades of steady, high-margin revenue. This is why investors who specifically look to target drug stocks are always aware of an upcoming FDA catalyst for that company. FDA approvals are bullish whether the company is a pre-revenue startup or a global pharmaceutical giant. At the same time, FDA rejections can tank a drug stock and erase years of gains in a single session. In this article, we’ll look at three companies that are awaiting key FDA decisions over the next couple of months. Depending on how that decision goes it could be a major catalyst that sends these stocks soaring in April. Merck & Co (MRK) Source: Sisacorn / Shutterstock.com Merck & Co (NYSE: MRK ) is an American multinational pharmaceutical company based out of New Jersey. It was originally the American division of Merck Group, a German company that was founded in 1668.
When the term blue chip is thrown around, many investors hear synonyms like stability and success. Other definitions limit blue-chip stocks to the 30 companies comprising the Dow Jones Industrial Average . However, blue chip stocks should be considered as those representing long-running and well-established companies that prioritize their financial health. Moreover, these companies typically command a market capitalization numbering in the billions or even trillions of dollars. This ensures both the volume of outstanding shares and their value is capable of protecting investors from severe market volatility. Ultimately, these company stocks are both trustworthy and well-known among consumers and investors alike. Unfortunately, no company’s success lasts forever , as the complex nature of the market and business landscape requires constant evolution. Even as the current U.S. stock market trends toward growth, earnings misses and revenue losses are possible for any major company. As such, investors might want to think about which blue chip stocks to sell should the market trends reverse.
Amgen Inc (AMGN) share price today is $269.98
Yes, Indians can buy shares of Amgen Inc (AMGN) on Vested. To buy Amgen Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in AMGN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Amgen Inc (AMGN) via the Vested app. You can start investing in Amgen Inc (AMGN) with a minimum investment of $1.
You can invest in shares of Amgen Inc (AMGN) via Vested in three simple steps:
The 52-week high price of Amgen Inc (AMGN) is $327.16. The 52-week low price of Amgen Inc (AMGN) is $206.75.
The price-to-earnings (P/E) ratio of Amgen Inc (AMGN) is 21.62
The price-to-book (P/B) ratio of Amgen Inc (AMGN) is 22.99
The dividend yield of Amgen Inc (AMGN) is 3.3%
The market capitalization of Amgen Inc (AMGN) is $144.81B
The stock symbol (or ticker) of Amgen Inc is AMGN
Link copied 
